These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 12714034

  • 1. HDL in atherosclerosis: actor or bystander?
    Asztalos BF, Schaefer EJ.
    Atheroscler Suppl; 2003 Mar; 4(1):21-9. PubMed ID: 12714034
    [Abstract] [Full Text] [Related]

  • 2. Beyond LDL-C--the importance of raising HDL-C.
    Wierzbicki AS, Mikhailidis DP.
    Curr Med Res Opin; 2002 Mar; 18(1):36-44. PubMed ID: 11999145
    [Abstract] [Full Text] [Related]

  • 3. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Mar; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Mar; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 6. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.
    JAMA; 2001 Mar 28; 285(12):1585-91. PubMed ID: 11268266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 28; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 9. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP, Lemieux I, Robins SJ.
    Drugs; 2004 Oct 28; 64(19):2177-98. PubMed ID: 15456334
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH, Maki KC, Karp SK, Ingram KA.
    Drugs Aging; 2002 Oct 28; 19(3):169-78. PubMed ID: 12027776
    [Abstract] [Full Text] [Related]

  • 12. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
    Brousseau ME, O'Connor JJ, Ordovas JM, Collins D, Otvos JD, Massov T, McNamara JR, Rubins HB, Robins SJ, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2002 Jul 01; 22(7):1148-54. PubMed ID: 12117730
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC, Medici F.
    Angiology; 1998 May 15; 49(5):339-48. PubMed ID: 9591525
    [Abstract] [Full Text] [Related]

  • 19. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 May 15; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.